Study EV-103 Cohort K: Antitumor activity of enfortumab vedotin (EV) monotherapy or in combination with pembrolizumab (P) in previously untreated cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (la/mUC)

被引：36
|
作者：
Rosenberg, J. E. [1 ]
Milowsky, M. [2 ]
Ramamurthy, C. [3 ]
Mar, N. [4 ]
Mckay, R. R. [5 ]
Friedlander, T. [6 ]
Ferrario, C. [7 ]
Bracarda, S. [8 ]
George, S. [9 ]
Moon, H. [10 ]
Geynisman, D. [11 ]
Petrylak, D. P. [12 ]
Borchiellini, D. [13 ]
Burgess, E. F. [14 ]
Rey, J. P. Maroto [15 ]
Carret, A-S. [16 ]
Yu, Y. [17 ]
Guseva, M. V. [18 ]
Moreno, B. Homet [19 ]
O'Donnell, P. H. [20 ]
机构：
[1] MSKCC Mem Sloan Kettering Canc Ctr, Med Dept, New York, NY USA
[2] Univ North Carolina Chapel Hill, Med Dept, Chapel Hill, NC USA
[3] Univ Texas Hlth Sci Ctr San Antonio, Mays Canc Ctr, Hematol, San Antonio, TX USA
[4] Univ Calif Irvine, UCI Hlth, Hematol Oncol, Orange, CA USA
[5] Univ Calif San Diego, Med Oncol, La Jolla, CA USA
[6] UCSF Univ Calif San Francisco, Oncol, San Francisco, CA USA
[7] Jewish Gen Hosp, Oncol, Montreal, PQ, Canada
[8] Azienda Osped Santa Maria, Med Translat Oncol Unit, Terni, Italy
[9] Roswell Pk Comprehens Canc Ctr, Med Dept, Buffalo, NY USA
[10] Kaiser Permanente Riverside Med Ctr, Oncol Dept, Riverside, CA USA
[11] Fox Chase Canc Ctr, Med Oncol Dept, Main Campus, Philadelphia, PA USA
[12] Yale Univ, Med Oncol Dept, Sch Med, New Heaven, CT USA
[13] Ctr Antoine Lacassagne, Oncol, Nice, France
[14] Levine Canc Inst, Dept Med Oncol, Charlotte, NC USA
[15] Hosp Santa Creu & Sant Pau, Dept Med Oncol, Barcelona, Spain
[16] Seagen Inc, Clin Dev, Bothell, WA USA
[17] Seagen Inc, Biostat, Bothell, WA USA
[18] Astellas Pharma USA, Oncol, Global Medica Affairs, Northbrook, IL USA
[19] Merck & Co Inc, Clin Res, Rahway, NJ USA
[20] Univ Chicago, Hematol & Oncol, Chicago, IL USA
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期
关键词：
D O I：
10.1016/j.annonc.2022.08.079
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA73
引用
收藏
页码：S1441 / S1441
页数：1
相关论文
共 50 条
  • [31] EV-201: Results of enfortumab vedotin monotherapy for locally advanced or metastatic urothelial cancer previously treated with platinum and immune checkpoint inhibitors.
    Petrylak, Daniel Peter
    Balar, Arjun Vasant
    O'Donnell, Peter H.
    McGregor, Bradley Alexander
    Heath, Elisabeth I.
    Yu, Evan Y.
    Galsky, Matt D.
    Hahn, Noah M.
    Gartner, Elaina M.
    Pinelli, Juan
    Melhem-Bertrandt, Amal
    Rosenberg, Jonathan E.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (18)
  • [32] EV-301: An open-label, randomized phase III study to evaluate enfortumab vedotin versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial cancer (la/mUC)
    Petrylak, D. P.
    Rosenberg, J.
    Duran, I.
    Loriot, Y.
    Sonpavde, G.
    Wu, C.
    Gartner, E.
    Melhem-Bertrandt, A.
    Powles, T.
    ANNALS OF ONCOLOGY, 2018, 29
  • [33] EV-103 study: A phase 1b dose-escalation and doseexpansion study of enfortumab vedotin in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer.
    Hoimes, Christopher J.
    Petrylak, Daniel Peter
    Flaig, Thomas W.
    Carret, Anne-Sophie
    Melhem-Bertrandt, Amal
    Rosenberg, Jonathan E.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [34] Enfortumab vedotin in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer who received prior PD-1/PD-L1 inhibitors: An updated analysis of EV-201 Cohort 2.
    McGregor, Bradley Alexander
    Balar, Arjun Vasant
    Rosenberg, Jonathan E.
    Van der Heijden, Michiel Simon
    Park, Se Hoon
    Lee, Jae-Lyun
    Kojima, Takahiro
    Harrison, Michael Roger
    Heath, Elisabeth I.
    Stein, Mark N.
    Loriot, Yohann
    Necchi, Andrea
    Steinberg, Joyce Leta
    Liang, Shang-Ying
    Trowbridge, Janet
    Petrylak, Daniel P.
    Yu, Evan Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [35] Patient-reported outcomes (PROs) from a randomized, phase 3 trial of enfortumab vedotin plus pembrolizumab (EV plus P) versus platinum-based chemotherapy (PBC) in previously untreated locally advanced or metastatic urothelial cancer (la/mUC)
    Gupta, Shilpa
    Loriot, Yohan
    Van Der Heijden, Michiel Simon
    Bedke, Jens
    Valderrama, Begona Perez
    Kikuchi, Eiji
    Flechon, Aude
    Petrylak, Daniel P.
    De Santis, Maria
    Galsky, Matt D.
    Lee, Jae-Lyun
    Swami, Umang
    Sridhar, Srikala S.
    De Giorgi, Ugo
    Wright, Phoebe
    Lu, Yi-Tsung
    Guan, Xuesong
    Dillon, Ryan
    Moreno, Blanca Homet
    Powles, Thomas
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [36] Patient-reported outcomes (PROs) from a randomized, phase 3 trial of enfortumab vedotin plus pembrolizumab (EV plus P) versus platinum-based chemotherapy (PBC) in previously untreated locally advanced or metastatic urothelial cancer (la/mUC).
    Gupta, Shilpa
    Loriot, Yohann
    van der Heijden, Michiel Simon
    Bedke, Jens
    Valderrama, Begona Perez
    Flechon, Aude
    Petrylak, Daniel P.
    De Santis, Maria
    Galsky, Matt D.
    Lee, Jae Lyun
    Swami, Umang
    Sridhar, Srikala S.
    De Giorgi, Ugo
    Wright, Phoebe
    Lu, Yi-Tsung
    Guan, Xuesong
    Dillon, Ryan
    Homet Moreno, Blanca
    Powles, Thomas
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (23_SUPPL) : 108 - 108
  • [37] Study EV-103: Neoadjuvant treatment with enfortumab vedotin monotherapy in cisplatinin-eligible patients (pts) with muscle invasive bladder cancer (MIBC): Updated results for Cohort H.
    Flaig, Thomas W.
    Rosenberg, Jonathan E.
    Hoimes, Christopher J.
    O'Donnell, Peter H.
    Mar, Nataliya
    Gourdin, Theodore Stewart
    Henry, Stephanie
    Bilen, Mehmet Asim
    George, Saby
    Barata, Pedro C.
    Srinivas, Sandy
    Rao, Santosh Keshay
    Assikis, Vasily J.
    Burgess, Earle F.
    Ramamurthy, Chethan
    Haas, Gabriel P.
    Lukas, Jason Jerome
    Mildiner-Earley, Shirly
    Yu, Yao
    Petrylak, Daniel P.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [38] Enfortumab vedotin (EV) in patients (Pts) with metastatic urothelial carcinoma (mUC) with prior checkpoint inhibitor (CPI) failure: A prospective cohort of an ongoing phase 1 study.
    Petrylak, Daniel Peter
    Smith, David C.
    Flaig, Thomas W.
    Zhang, Jingsong
    Sridhar, Srikala S.
    Ruether, Joseph D.
    Plimack, Elizabeth R.
    Merchan, Jaime R.
    Quinn, David I.
    Kilari, Deepak
    Srinivas, Sandy
    Baranda, Joaquina Celebre
    Lang, Joshua Michael
    Milowsky, Matthew I.
    Galsky, Matt D.
    Spira, Alexander I.
    Gartner, Elaina M.
    Wu, Chunzhang
    Melhem-Bertrandt, Amal
    Rosenberg, Jonathan E.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [39] KEYNOTE-905/EV-303: A phase 3 study of perioperative pembrolizumab or pembrolizumab plus enfortumab vedotin and cystectomy versus cystectomy alone in cisplatin-ineligible patients with muscle-invasive bladder cancer
    Hennika, Tammy
    Galsky, Matthew D.
    Necchi, Andrea
    Shore, Neal D.
    Plimack, Elizabeth
    Jia, Calvin
    Moreno, Blanca Homet
    Witjes, J. Alfred
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2021, 17 : 207 - 208
  • [40] PIVOT-10: A phase II study of bempegaldesleukin (NKTR-214) in combination with nivolumab (NIVO) in cisplatin (cis) ineligible patients with previously untreated locally advanced or metastatic urothelial cancer (mUC)
    Huddart, Robert A.
    Siefker-Radtke, Arlene O.
    Balar, Arjun Vasant
    Bilen, Mehmet Asim
    Powles, Thomas
    Bamias, Aristotelis
    Castellano, Daniel
    Khalil, Maged F.
    Van der Heijden, Michiel Simon
    Koshkin, Vadim S.
    Pook, David William
    Ozguroglu, Mustafa
    Santiago, Linda
    Saab, Rabih
    Li, Pao-Chen
    Tagliaferri, Margit Cecile
    Lin, Wei
    Tagliaferri, Mary Ann
    Loriot, Yohann
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
12345